The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).
 
Chloe Evelyn Atreya
Speakers' Bureau - Bayer
Research Funding - GlaxoSmithKline
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
 
Johanna C. Bendell
No Relationships to Disclose
 
Thierry Andre
Honoraria - Amgen; Bayer; Merck; Roche Pharma AG; Sanofi
Consulting or Advisory Role - Amgen; Bayer; Roche Pharma AG; Sanofi
 
Jan H. M. Schellens
No Relationships to Disclose
 
Michael S. Gordon
Research Funding - GlaxoSmithKline; MedImmune
 
Autumn Jackson McRee
Consulting or Advisory Role - Grand Rounds
 
Peter J O'Dwyer
Stock and Other Ownership Interests - TetraLogic Pharmaceuticals
Consulting or Advisory Role - Five Prime Therapeutics; Genentech
Research Funding - Bayer; BBI Healthcare; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Millennium; Mirati Therapeutics; Novartis
Expert Testimony - Lilly
 
Kei Muro
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical
 
Robin van Geel
No Relationships to Disclose
 
Roger Sidhu
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
James G Greger
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Fatima A. Rangwala
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Monica Motwani
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
Other Relationship - GlaxoSmithKline
 
Yuehui Wu
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Keith W. Orford
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Ryan Bruce Corcoran
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - Avidity Nanomedicines; Merrimack; Taiho Pharmaceutical